Curaleaf (OTCMKTS:CURLF) Shares Down 3.3% – Here’s Why

Shares of Curaleaf Holdings, Inc. (OTCMKTS:CURLF) were down 3.3% on Monday . The company traded as low as $2.85 and last traded at $2.92. Approximately 367,347 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 870,768 shares. The stock had previously closed at $3.0190.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CURLF. Alliance Global Partners reaffirmed a “buy” rating on shares of Curaleaf in a research note on Monday. Canaccord Genuity Group upgraded shares of Curaleaf to a “strong-buy” rating in a research report on Thursday, October 9th. ATB Capital upgraded Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Finally, Atb Cap Markets upgraded Curaleaf from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 2nd. Two equities research analysts have rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Strong Buy”.

Curaleaf Stock Down 2.2%

The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.71 and a current ratio of 1.47. The company’s fifty day moving average price is $2.74 and its 200-day moving average price is $2.26. The stock has a market cap of $1.87 billion, a P/E ratio of -8.62 and a beta of 0.77.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%. Equities analysts forecast that Curaleaf Holdings, Inc. will post -0.25 EPS for the current year.

About Curaleaf

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.